Generation of antibody-drug conjugates by proximity-based sortase-mediated ligation

通过基于邻近的分选酶介导的连接生成抗体-药物缀合物

基本信息

批准号：
10323853
负责人：
Feifan Yu
金额：
$ 108.12万
依托单位：
ALPHATHERA, INC.
依托单位国家：
美国
项目类别：
财政年份：
2017
资助国家：
美国
起止时间：
2017-08-01 至 2023-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10323853
关键词：
Adult Amino Acid Sequence Antibodies Antibody Avidity Antibody Formation Antibody Specificity Antibody-drug conjugates Binding Biodistribution Biological Assay Blood Circulation C-terminal Chemicals Chemistry Clinical Comparative Pathology Cysteine Data Development Disulfides Drug Industry Drug Kinetics Drug Stability Effectiveness Engineering Enzymes Exposure to FDA approved Formulation Generations Goals Human Hydrophobicity IgG Receptors IgG1 Immunocompetent Immunoglobulin G In Vitro Intravenous Label Lead Ligation Location Lysine Malignant Neoplasms Malignant neoplasm of pancreas Measurable Mediating Methods Modality Modeling Modification Molecular Movement Mus Outcome Pennsylvania Peptides Pharmaceutical Preparations Polysaccharides Preclinical Testing Preparation Property Proteins Serum Site Solubility Technology Testing Therapeutic Time Tissues Toxic effect Transglutaminases Universities Variant Vertebral column antibody engineering antitumor drug base cancer therapy chemotherapy clinical translation cytotoxic cytotoxicity effective therapy enzyme activity experience flexibility formylglycine glycosylated IgG interest lead candidate neonatal Fc receptor neoplastic cell novel strategies novel therapeutics pancreatic cancer model pancreatic cancer patients selective expression sortase targeted treatment tumor unnatural amino acids

项目摘要

There has been growing interest in the use of antibody drug conjugates (ADCs) for the treatment of cancer as mounting data suggests an increase in anti-tumor effectiveness and reduced toxicity, compared with the administration of unlabeled antibodies in combination with chemotherapy. Recent evidence has shown that differentially labeled antibodies, i.e. labeled at different locations and with different numbers, can have distinct therapeutic and pharmacokinetic properties and some subpopulations can show little, if any, therapeutic activity yet account for most of the toxicity. Therefore, there has been a movement towards the development of site- specific ADCs, which are precisely labeled with drugs at pre-defined locations. We have recently developed two new approaches for the preparation of highly uniform ADCs, one site-specific bioconjugation approach, Proximity-Based Sortase-mediated protein Ligation (PBS-PL), whereby sortase is used to ligate drugs to a peptide tag that has been introduced into the antibody backbone, and one region- specific bioconjugation approach, Proximity-based Sortase Isopeptide Ligation (PBS-IL), which allows for the labeling of native antibodies with reduced variability compared with current lysine/cysteine residue labeling approaches. Both methods produce ADCs in high yields, are compatible with glycosylated IgG, and offer unlimited flexibility in antibody-drug linker chemistry. Therefore, we believe that these technologies will provide new, favorable approaches for the production of ADCs that will be of interest to the pharmaceutical industry. In this proposal, we have partnered with Integral Molecular and the University of Pennsylvania to develop ADCs against claudin-18 (CLDN 18.2). CLD18.2 is ectopically expressed in several cancers including pancreatic cancer, which is the focus of this proposal. Outcomes for pancreatic cancer patients are poor with a 5-year survival of <8% due to a lack of effective treatment modalities. Therefore, the development of new therapies are a clinical necessity. The highly selective expression of CLDN18.2 in cancer, with no detectable expression on any healthy adult tissues that are accessible to antibodies, make it an attractive option for targeted therapy. We will prepare various ADCs using PBS-PL and PBS-IL and will identify the conjugation approach and ADC formulation that is expected to be most favorable for clinical translation, based on serum stability, pharmacokinetics, and efficacy. Pre-clinical testing will be performed in an orthotopic pancreatic tumor model in syngeneic mice. The specific aims for the proposal are: Aim 1: Produce and characterize anti- CLDN18.2-vcMMAE ADCs using PBS-PL and PBS-IL; Aim 2: Evaluate the binding and efficacy of anti- CLDN18.2-vcMMAE ADCs in vitro; Aim 3. Determine the pharmacokinetics and efficacy of anti-CLDN18.2 ADCs in a murine tumor model

人们对使用抗体药物偶联物 (ADC) 治疗癌症越来越感兴趣，因为越来越多的数据表明，与与化疗联合施用未标记的抗体。最近的证据表明差异标记的抗体，即在不同的位置和用不同的数字进行标记，可以具有不同的治疗和药代动力学特性，某些亚群可能表现出很少的治疗活性（如果有的话）但造成了大部分毒性。因此，出现了网站开发的趋势—— 特定的 ADC，在预先定义的位置精确地标记了药物。我们最近开发了两种制备高度均匀 ADC 的新方法，一种是位点特异性的生物缀合方法，基于邻近分选酶介导的蛋白质连接（PBS-PL），其中分选酶是用于将药物连接到已引入抗体主链的肽标签，以及一个区域- 特定的生物缀合方法，基于邻近的分选酶异肽连接（PBS-IL），它允许与目前的赖氨酸/半胱氨酸残基标记相比，天然抗体的标记变异性降低接近。两种方法都能以高产率生产 ADC，与糖基化 IgG 兼容，并提供抗体-药物连接体化学的无限灵活性。因此，我们相信这些技术将提供生产 ADC 的新的、有利的方法将引起制药行业的兴趣。在这项提案中，我们与 Integral Molecular 和宾夕法尼亚大学合作开发针对claudin-18 (CLDN 18.2) 的 ADC。 CLD18.2 在多种癌症中异位表达，包括胰腺癌，这是该提案的重点。胰腺癌患者的预后很差由于缺乏有效的治疗方式，5年生存率<8%。因此，开发新的治疗是临床必需的。 CLDN18.2在癌症中高度选择性表达，未检测到在任何可接触到抗体的健康成人组织上表达，使其成为一个有吸引力的选择靶向治疗。我们将使用 PBS-PL 和 PBS-IL 制备各种 ADC，并识别缀合基于血清的方法和 ADC 配方预计最有利于临床转化稳定性、药代动力学和功效。临床前测试将在原位胰腺肿瘤中进行同基因小鼠模型。该提案的具体目标是：目标 1：产生并表征反使用 PBS-PL 和 PBS-IL 的 CLDN18.2-vcMMAE ADC；目标 2：评估抗- CLDN18.2-vcMMAE ADC 体外；目标 3. 确定抗 CLDN18.2 的药代动力学和功效小鼠肿瘤模型中的 ADC